Other languages Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Real-time Estimate Cboe BZX Other stock markets 16:50:31 29/04/2024 BST			5-day change	1st Jan Change
5.915 ^USD	+0.77%		+9.87%	-2.80%

04-24	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
04-24	Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	04-24
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	04-24
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	04-18
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	04-12
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	04-08
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment	03-25
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	03-25
Sector Update: Health Care Stocks Edge Higher Premarket Friday	03-01
Sector Update: Health Care	03-01
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Friday as Traders Turn Cautious After Major US Data Releases	03-01
Top Premarket Gainers	03-01
Stock Futures Decrease Pre-Bell as Earnings Season Winds Down; Asia, Europe Fall	03-01
Amneal Pharmaceuticals' Q4 Adjusted Earnings Decline, Revenue Increases; Sets 2024 Guidance; Shares Rise	03-01
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	03-01
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-01
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-01
Amneal Pharmaceuticals Licenses Parkinson's Drug to Zambon Biotech in EU	02-27
Amneal Grants Knight Therapeutics Rights to Parkinson's Disease Drug in Canada, Latin America	01-25
Knight Therapeutics Inc. Enters into Exclusive License Agreement with Amneal Pharmaceuticals, Inc. for IPX203	01-25
Amneal Pharmaceuticals Launches Generic Fluorometholone Ophthalmic Suspension	01-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Other languages

Filters